STOCK TITAN

Shareholder in OCUL (NASDAQ: OCUL) to sell 3,052 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A shareholder of OCUL filed a notice of proposed sale under Rule 144 for 3,052 shares of common stock, with an aggregate market value of $27,903.83. The shares were acquired on 01/30/2026 through restricted stock vesting under a registered plan.

The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 02/02/2026. OCUL had 213,047,472 shares of common stock outstanding at the time referenced.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the OCUL Form 144 filing disclose?

The Form 144 filing discloses a proposed sale of 3,052 OCUL common shares by a shareholder. The shares, valued at $27,903.83 in total, are planned to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services.

How many OCUL shares are planned to be sold and at what value?

The filing indicates a planned sale of 3,052 OCUL common shares with an aggregate market value of $27,903.83. This figure is based on market pricing at the time of the notice and reflects the total value of the proposed transaction.

How were the OCUL shares being sold under Form 144 acquired?

The OCUL shares were acquired on 01/30/2026 through restricted stock vesting under a registered plan. The issuer granted 3,052 common shares, which vested and became eligible for sale, prompting the shareholder to file the Rule 144 notice.

When is the OCUL shareholder planning to sell the shares?

The Form 144 states an approximate sale date of 02/02/2026. This indicates the shareholder’s intention to begin selling 3,052 OCUL common shares around that date, subject to market conditions and compliance with Rule 144 requirements.

Which broker and exchange are involved in the OCUL share sale?

The proposed sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located in New York. The 3,052 OCUL common shares are planned to be sold on the NASDAQ exchange, as specified in the Form 144 filing.

How many OCUL shares were outstanding at the time of the notice?

The filing reports that 213,047,472 OCUL common shares were outstanding. This number provides context for the planned sale of 3,052 shares, showing the broader share base against which this individual transaction occurs.
Ocular Therapeut

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

1.81B
206.17M
3.33%
90.81%
7.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD